aTyr Pharma, Inc. (NASDAQ:ATYR) Receives $25.67 Average Price Target from Analysts

Shares of aTyr Pharma, Inc. (NASDAQ:ATYR) have received an average rating of “Hold” from the seven analysts that are presently covering the firm, MarketBeat reports. One research analyst has rated the stock with a sell recommendation, five have assigned a hold recommendation and one has given a buy recommendation to the company. The average 1-year target price among analysts that have issued a report on the stock in the last year is $25.6667.

A number of research analysts recently weighed in on ATYR shares. Weiss Ratings reiterated a “sell (d-)” rating on shares of aTyr Pharma in a report on Monday, December 29th. Wall Street Zen upgraded aTyr Pharma from a “sell” rating to a “hold” rating in a report on Sunday, March 15th. Finally, Jefferies Financial Group reaffirmed a “buy” rating on shares of aTyr Pharma in a research note on Friday, March 6th.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently bought and sold shares of the business. Vanguard Group Inc. grew its stake in aTyr Pharma by 21.0% during the third quarter. Vanguard Group Inc. now owns 5,630,935 shares of the company’s stock worth $4,060,000 after buying an additional 975,887 shares during the period. UBS Group AG raised its stake in shares of aTyr Pharma by 158.1% in the 3rd quarter. UBS Group AG now owns 4,505,955 shares of the company’s stock valued at $3,249,000 after acquiring an additional 2,760,238 shares during the period. Octagon Capital Advisors LP lifted its holdings in shares of aTyr Pharma by 7.5% during the 2nd quarter. Octagon Capital Advisors LP now owns 3,820,000 shares of the company’s stock valued at $19,367,000 after acquiring an additional 268,000 shares in the last quarter. GSA Capital Partners LLP lifted its holdings in shares of aTyr Pharma by 272.2% during the 4th quarter. GSA Capital Partners LLP now owns 2,630,638 shares of the company’s stock valued at $2,060,000 after acquiring an additional 1,923,907 shares in the last quarter. Finally, Geode Capital Management LLC boosted its position in aTyr Pharma by 4.8% during the 4th quarter. Geode Capital Management LLC now owns 2,283,717 shares of the company’s stock worth $1,789,000 after purchasing an additional 105,514 shares during the period. 61.72% of the stock is owned by institutional investors and hedge funds.

aTyr Pharma Stock Down 3.5%

NASDAQ:ATYR opened at $0.82 on Friday. The company has a market cap of $80.74 million, a P/E ratio of -1.04 and a beta of 0.64. The firm’s 50 day moving average is $0.88 and its two-hundred day moving average is $0.83. aTyr Pharma has a fifty-two week low of $0.64 and a fifty-two week high of $7.29.

aTyr Pharma (NASDAQ:ATYR) last announced its quarterly earnings data on Thursday, March 5th. The company reported ($0.14) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.18) by $0.04. Research analysts forecast that aTyr Pharma will post -0.59 earnings per share for the current fiscal year.

aTyr Pharma Company Profile

aTyr Pharma, Inc is a clinical-stage biotechnology company focused on the discovery and development of novel protein-based therapies that modulate the extracellular matrix and immune pathways. Headquartered in San Diego, California, the company applies its proprietary Extracellular Modulation® platform to identify and optimize biologic candidates for the treatment of rare and serious diseases, including pulmonary sarcoidosis, muscular dystrophy, and solid tumors.

The company’s research efforts are centered on harnessing extracellular proteins to regulate tissue remodeling, cell adhesion, and immune signaling.